CCTG IND.239: A phase 2 study of combined CFI-400945 and durvalumab in patients with advanced triple negative breast cancer (aTNBC)
John Hilton,David W. Cescon,Andrew Robinson,Sukhbinder Dhesy-Thind, Sara Taylor,Arif Awan,Terry L. Ng,Moira Rushton,Marie-France Savard, Lindsay Muyot, Marie Claude Reeves,Linda Hagerman,Hongbo Lui,Mark Bray,Dongsheng Tu,Lesley Seymour,Pierre-Olivier Gaudreau CANCER RESEARCH（2023）
AI 理解论文
溯源树
样例
